Clinical trials: Influenza Vaccine
Influenza, Influenza-like Illness
A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD
A total of 18,000 eligible subjects (or 6,000 subject distributed evenly between the 3 study arms) will be enrolled. Eligible subjects will be randomized in 1:1:1 (cell-culture-based vaccine, the recombinant vaccine, or the…
- Conditions
- Influenza, Influenza-like Illness, Influenza Vaccines
- Trial name
- PAIVED (NCT03734237)
- Testing
- Egg based influenza vaccines, Recombinant influenza vaccines, Cell-culture based influenza vaccines
- Where
- 9 sites in United States
- Volunteers
- 15,448 people, healthy volunteers welcome
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Vaccine Response
Systems Biological Assessment of Statin Effect on Vaccine Responses
This study is being done to answer the question: Does the use of statin lipid-lowering medication change the effect of influenza vaccine? The research team will use the knowledge gained from answering this question to understand…
- Trial name
- NCT06024096
- Testing
- Atorvastatin, Quadrivalent seasonal influenza vaccine
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Emory University
Health Behavior, Colorectal Cancer
Building Engagement Using Financial Incentives Trial - Colorectal Cancer Screening
The goal of this pilot clinical trial is to determine feasibility and explore whether financial incentives paid to primary care patients for completing colorectal cancer screening increase completion of colorectal cancer…
- Conditions
- Health Behavior, Colorectal Cancer, Influenza, COVID-19
- Trial name
- BENEFIT-C (NCT06124131)
- Testing
- Financial incentive for colorectal cancer screening, Financial incentive for flu shot, Financial incentive for COVID-19 shot
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Tulane University
Influenza, Vaccine Hesitancy
Precision Vaccine Promotion in Underserved Populations
Previous studies have shown that low-cost, behavioral nudges through texting can increase influenza vaccination uptake compared to usual care.
- Trial name
- NCT05537441
- Testing
- Text messaging
- Where
- United States
- Volunteers
- 228,831 people
- Sponsor
- University of Southern California
Vaccine Refusal
Promoting Altruism to Enhance Vaccine Acceptance
Subjects enrolled in this study are eligible for the seasonal influenza vaccine. The purpose of this research study is to figure out if increasing individuals' awareness of the benefits of herd immunity, specifically to the local…
- Trial name
- NCT04568590
- Testing
- educational intervention
- Where
- United States
- Volunteers
- 510 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Influenza Vaccines
Assessment of Viral Shedding Week Following Administration of Live Attenuated Influenza Vaccine in Children
LAIV shedding studies in children could be an important way to confirm whether impediments to viral replication do indeed explain these observed reductions in vaccine effectiveness (VE), whether prior vaccination has any…
- Trial name
- FluSHED-2 (NCT03735147)
- Testing
- Live attenuated influenza vaccine (LAIV)
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Influenza Vaccine
Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old
This is a randomized, double-blind, placebo-controlled Phase 1b study to evaluate safety and immunogenicity of the investigational Sing2016 M2SR H3N2 influenza vaccine delivered intranasally to a healthy adult population age 50…
- Trial name
- NCT04785794
- Testing
- Sing2016 M2SR H3N2 influenza vaccine
- Where
- 3 sites in United States
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- FluGen Inc
Flu Vaccine
Senescent Immunity in Elders and Vaccine Responses (SILVER)
To study the effects of age on the immune system's response to flu vaccine and to study the connection between the immune system and physical and cognitive changes associated with aging.
- Trial name
- NCT04077424
- Testing
- Fluzone-High Dose Quadrivalent, Fluad, Flublock
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Influenza, Vaccine Virus Shedding
Nasal and Systemic Immune Responses to Nasal Influenza Vaccine
Intranasal live attenuated influenza vaccine (LAIV; trade name FluMist/Fluenz-Tetra, manufactured by AstraZeneca/Medimmune) is the standard influenza vaccine given to children aged 2-17 years of age in the UK.
- Trial name
- Flu-M3 (NCT04110366)
- Testing
- Live attenuated influenza vaccine, Vehicle control
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Imperial College Healthcare NHS Trust
Influenza, Respiratory Tract Infections
Patient Portal - Flu Reminder Recall
This trial is taking place in Los Angeles, CA at clinics within the UCLA Health System. Despite the Advisory Committee on Immunization Practices (ACIP) recommendation in 2010 that all people above 6 months of age should receive…
- Conditions
- Influenza, Respiratory Tract Infections, Vaccines
- Trial name
- NCT03666026
- Testing
- 1 MyChart R/R, 2 MyChart R/R, 3 MyChart R/R
- Where
- United States
- Volunteers
- 164,205 people
- Sponsor
- University of California, Los Angeles
Influenza, Influenza Vaccines
Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age
This study will assess safety and immunogenicity of GSK Biologicals' H5N1 flu candidate vaccine GSK1557484A in children 6 months to < 18 years of age.
- Trial name
- NCT01310413
- Testing
- Influenza A (H5N1) Virus monovalent vaccine
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 842 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza Vaccine
A Phase 2 Study to Evaluate Immune Responses of FluMist®
The primary objective of this study is to describe the level of serum antibody and cellular immune responses conferred by FluMist and TIV against influenza virus strains.
- Trial name
- NCT00461981
- Testing
- TIV, Trivalent Inactivated Influenza Virus Vaccine, FluMist, Influenza Virus Vaccine Live
- Where
- 19 sites in United States
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Asthma in Children, Vaccine Adverse Reaction
Safety of LAIV4 in Children With Asthma
This is a prospective randomized, open label clinical trial in approximately 300 children aged 5-11 years with a physician diagnosis of persistent asthma.
- Conditions
- Asthma in Children, Vaccine Adverse Reaction, Vaccine Reaction, Asthma
- Trial name
- NCT03600428
- Testing
- Live Attenuated Influenza Vaccine (LAIV), Inactivated Influenza Vaccine (IIV)
- Where
- 3 sites in United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Influenza, Vaccine
Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine
The clinical study will evaluate safety and the immune response of a prime- boost regimen with a live attenuated influenza vaccine (LAIV) prime and an inactivated split influenza vaccine (IIV) boost with or without adjuvant.
- Trial name
- NCT03300050
- Testing
- cH8/1N1 LAIV, AS03-adjuvanted cH5/1N1 IIV, cH5/1N1 IIV
- Where
- 2 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- PATH
Influenza, Influenza Vaccines
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
The purpose of this observer-blind study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' influenza vaccine GSK2584786A in healthy children 6 to 35 months of age.
- Trial name
- NCT01195779
- Testing
- GSK Bio's influenza vaccine GSK2584786A, different formulations, GSK Bio's influenza vaccine GSK2321138A, Fluarix™
- Where
- Spain
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Influenza Vaccines
Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure
The purpose of this study is to evaluate the safety and tolerability of GSK Biologicals' vaccine GSK1557484A against pandemic avian (H5N1) influenza in adults at occupational risk of exposure to the virus.
- Trial name
- NCT01788228
- Testing
- Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)
- Where
- 3 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Influenza Vaccines
Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults
The present study is designed to assess the lot-to-lot consistency of the immunogenicity of a GlaxoSmithKline Biologicals' pandemic influenza candidate vaccine (GSK1562902A) in adults aged between 18 and 60 years.
- Trial name
- NCT00449670
- Testing
- H5N1 adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain), H5N1 non-adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain), H5N1 adjuvanted split virus vaccine (A/Indonesia/05/2005 strain)
- Where
- 6 sites in Hong Kong, Singapore and 2 more
- Volunteers
- 1,206 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Influenza Vaccines
Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population
Influenza pandemics are caused by viruses that possess an Hemagglutinin molecule to which most of the population lacks immunity.
- Trial name
- NCT00306995
- Testing
- SB218352_15, SB218352_8, SB218352_4
- Where
- 10 sites in Germany
- Volunteers
- 385 people
- Sponsor
- GlaxoSmithKline
Influenza Vaccines Efficacy and Safety
Efficacy & Safety of Nasal Influenza Immunisation in Children
The UK Departments of Health now recommend annual influenza vaccination for all children 2-7 years of age, with children over 7 years eligible for vaccination if in certain higher risk clinical categories.
- Trial name
- SNIFFLE-3 (NCT02549365)
- Testing
- Live attenuated influenza vaccine, Surveillance (nasal swabbing) during influenza season
- Where
- United Kingdom
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Influenza, Influenza Vaccines
Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A)
The aim of the study is to assess the safety \& immunogenicity of a pandemic influenza vaccine administered at 2 different time points. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
- Trial name
- NCT00430521
- Testing
- Pandemic influenza vaccine (GSK1119711A)-formulation 1, Pandemic influenza vaccine (GSK1119711A)-formulation 2
- Where
- 10 sites in Germany
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline